Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aclaris Therapeutics, Inc.ACRS · Entity 5041 | Director · CEO | February 02, 2026 | February 06, 2026 |
| Aldeyra Therapeutics, Inc.ALDX · Entity 6839 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aclaris Therapeutics, Inc.
Report date February 02, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 274,800 |
Reported balance
After 2026-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 274,800 · Balance 274,800 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2036-02-01 | Direct | 961,700 |
Reported balance
After 2026-02-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-02 · Grant · Acquired 961,700 · Balance 961,700 F3: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F3: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
Aldeyra Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2036-06-08 | Direct | 70,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 70,000 · Balance 70,000 F1: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2036-06-08 | Direct | 3,318 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 3,318 · Balance 3,318 F2: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
F2: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2020 Filed Mar 4, 2020 21:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 96,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-016095 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,025,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 00:13 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 10,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-006668 · doc4.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,600 Underlying: Common Stock · 10,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 00:13 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 3,675 | $1.28 | $4,704.00 |
DisclosureSEC source: 0001209191-20-006668 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 928,903 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 00:13 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 10,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-006668 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 932,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:19 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 2,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-061545 · doc4.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,925 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On December 18, 2015, the reporting person was granted 11,700 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: On December 18, 2015, the reporting person was granted 11,700 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:19 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 743 | $1.81 | $1,344.83 |
DisclosureSEC source: 0001209191-19-061545 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 921,778 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:19 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 2,925 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-061545 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 922,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 16:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 3,033 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-061069 · doc4.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,034 Underlying: Common Stock · 3,033 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On December 15, 2016, the reporting person was granted 24,266 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: On December 15, 2016, the reporting person was granted 24,266 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 16:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 782 | $1.80 | $1,407.60 |
DisclosureSEC source: 0001209191-19-061069 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 919,596 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 16:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 3,033 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-061069 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 21:34 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,102 | $0.00 Strike: $7.06 | $0.00 |
DisclosureSEC source: 0000899243-19-015819 · doc4.xml · derivative · entry 2 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,102 Underlying: Common Stock · 1,102 shares Expires 2029-06-03 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 21:34 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 18,951 | $0.00 Strike: $7.06 | $0.00 |
DisclosureSEC source: 0000899243-19-015819 · doc4.xml · derivative · entry 1 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,951 Underlying: Common Stock · 18,951 shares Expires 2029-06-03 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 23:12 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 384,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-015894 · doc4.xml · derivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,600 Underlying: Common Stock · 384,600 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F2 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 23:34 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 10,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-007490 · doc4.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,400 Underlying: Common Stock · 10,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 23:34 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 3,579 | $6.96 | $24,909.84 |
DisclosureSEC source: 0001209191-19-007490 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 917,345 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 23:34 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 10,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-007490 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 18, 2018 Filed Dec 21, 2018 12:33 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 2,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-063804 · doc4.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,925 Underlying: Common Stock · 2,925 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On December 18, 2015, the reporting person was granted 11,700 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: On December 18, 2015, the reporting person was granted 11,700 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| December 18, 2018 Filed Dec 21, 2018 12:33 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 833 | $6.30 | $5,247.90 |
DisclosureSEC source: 0001209191-18-063804 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 910,124 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| December 18, 2018 Filed Dec 21, 2018 12:33 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 2,925 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-063804 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 910,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 15, 2018 Filed Dec 19, 2018 01:54 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 3,033 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-063373 · doc4.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,067 Underlying: Common Stock · 3,033 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On December 15, 2016, the reporting person was granted 24,266 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: On December 15, 2016, the reporting person was granted 24,266 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| December 15, 2018 Filed Dec 19, 2018 01:54 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 863 | $7.31 | $6,308.53 |
DisclosureSEC source: 0001209191-18-063373 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 908,032 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| December 15, 2018 Filed Dec 19, 2018 01:54 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 3,033 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-063373 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 908,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:36 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 903 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0000899243-18-015769 · doc4.xml · derivative · entry 2 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 903 Underlying: Common Stock · 903 shares Expires 2028-06-06 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:36 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 15,526 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0000899243-18-015769 · doc4.xml · derivative · entry 1 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,526 Underlying: Common Stock · 15,526 shares Expires 2028-06-06 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| May 07, 2018 Filed May 9, 2018 20:22 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 12,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-028863 · doc4.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,100 Underlying: Common Stock · 12,133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On December 15, 2016, the reporting person was granted 24,266 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: On December 15, 2016, the reporting person was granted 24,266 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| May 07, 2018 Filed May 9, 2018 20:22 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 3,455 | $18.10 | $62,535.50 |
DisclosureSEC source: 0001209191-18-028863 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 905,862 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| May 07, 2018 Filed May 9, 2018 20:22 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 12,133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-028863 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 909,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 12:38 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 10,000 | $16.75 | $167,500.00 |
DisclosureSEC source: 0001209191-18-024272 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 897,184 F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on March 20, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.50 to $17.10, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 16, 2018 Filed Mar 20, 2018 20:59 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | OtherCommon Stock | 9,018 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-020915 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 887,184 F1 · kind: Pro rata distribution from NST, LLC, of which the reporting person is a non-managing member, in accordance with NST, LLC's Limited Liability Company Operating Agreement. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:19 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 43,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-007455 · doc4.xml · derivative · entry 2 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,200 Underlying: Common Stock · 43,200 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:19 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock option (right to buy) · Derivative | 151,200 | $0.00 Strike: $22.09 | $0.00 |
DisclosureSEC source: 0001209191-18-007455 · doc4.xml · derivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,200 Underlying: Common Stock · 151,200 shares Expires 2028-01-31 F1 · derivative.exercise_date: The option will vest over a period of four years, with 25% of the shares underlying the option vesting on the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 18, 2017 Filed Dec 21, 2017 21:58 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 2,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066821 · doc4.xml · derivative · entry 6 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,850 Underlying: Common Stock · 2,925 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On December 18, 2015, the reporting person was granted 11,700 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F4 · derivative.expiration_date: On December 18, 2015, the reporting person was granted 11,700 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| December 18, 2017 Filed Dec 21, 2017 21:58 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 889 | $24.12 | $21,442.68 |
DisclosureSEC source: 0001209191-17-066821 · doc4.xml · nonDerivative · entry 4 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 878,166 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| December 18, 2017 Filed Dec 21, 2017 21:58 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 2,925 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-066821 · doc4.xml · nonDerivative · entry 3 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 879,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 15, 2017 Filed Dec 21, 2017 21:58 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 3,033 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066821 · doc4.xml · derivative · entry 5 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,233 Underlying: Common Stock · 3,033 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On December 15, 2016, the reporting person was granted 24,266 restricted stock units, with 50% of the shares underlying the restricted stock units vesting in four equal annual installments beginning on December 15, 2017 and the other 50% of the shares underlying these restricted stock units vesting upon the achievement of a specified commercial milestone, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: On December 15, 2016, the reporting person was granted 24,266 restricted stock units, with 50% of the shares underlying the restricted stock units vesting in four equal annual installments beginning on December 15, 2017 and the other 50% of the shares underlying these restricted stock units vesting upon the achievement of a specified commercial milestone, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| December 15, 2017 Filed Dec 21, 2017 21:58 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 922 | $24.23 | $22,340.06 |
DisclosureSEC source: 0001209191-17-066821 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 876,130 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| December 15, 2017 Filed Dec 21, 2017 21:58 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 3,033 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-066821 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 877,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:06 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 1,481 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0000899243-17-016103 · doc4.xml · derivative · entry 2 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,481 Underlying: Common Stock · 1,481 shares Expires 2027-06-07 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:06 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 17,776 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0000899243-17-016103 · doc4.xml · derivative · entry 1 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,776 Underlying: Common Stock · 17,776 shares Expires 2027-06-07 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| December 18, 2016 Filed Dec 20, 2016 23:49 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 2,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-156175 · doc4.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,775 Underlying: Common Stock · 2,925 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On December 18, 2015, the reporting person was granted 11,700 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: On December 18, 2015, the reporting person was granted 11,700 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| December 18, 2016 Filed Dec 20, 2016 23:49 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 889 | $31.25 | $27,781.25 |
DisclosureSEC source: 0001209191-16-156175 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 874,019 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| December 18, 2016 Filed Dec 20, 2016 23:49 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 2,925 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-156175 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 874,908 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 22:21 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 24,266 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-155966 · doc4.xml · derivative · entry 2 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,266 Underlying: Common Stock · 24,266 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: Subject to the reporting person's continuous service with the issuer as of the applicable vesting date, 50% of the shares underlying these restricted stock units will vest in four equal annual installments beginning on December 15, 2017 and the other 50% of the shares underlying these restricted stock units will vest upon the achievement of a specified commercial milestone. F3 · derivative.expiration_date: Subject to the reporting person's continuous service with the issuer as of the applicable vesting date, 50% of the shares underlying these restricted stock units will vest in four equal annual installments beginning on December 15, 2017 and the other 50% of the shares underlying these restricted stock units will vest upon the achievement of a specified commercial milestone. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 22:21 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock option (right to buy) · Derivative | 145,600 | $0.00 Strike: $28.92 | $0.00 |
DisclosureSEC source: 0001209191-16-155966 · doc4.xml · derivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,600 Underlying: Common Stock · 145,600 shares Expires 2026-12-14 F1 · derivative.exercise_date: The option will vest over a period of four years, with 25% of the shares underlying the option vesting on the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 23:06 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | OtherCommon Stock | 4,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142068 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 871,983 F2 · kind: Pro rata distribution from NST, LLC, of which the reporting person is a non-managing member, in accordance with NST, LLC's Limited Liability Company Operating Agreement. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 23:06 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | OtherCommon Stock | 81,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142068 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 867,193 F1 · kind: Liquidating distribution from NeXeption, LLC, of which the reporting person is a non-managing member, in accordance with NeXeption, LLC's Limited Liability Company Operating Agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.